Low-dose aspirin does not prevent pre-eclampsia, low birth weight in high-risk women | Latest news for doctors, nurses and pharmacists

Among women considered to be at high risk for pre-eclampsia by Doppler examination, treatment with low-dose aspirin appears to have no significant clinical benefit, according to a recent study.

Researchers conducted a randomized, blinded, parallel-group trial of 1,110 women who received 160 mg of aspirin (n=550) or a placebo (n=550). All participants had a lowest pulsatility index >1.7 or a bilateral protodiastolic notch or both uterine arteries as determined by ultrasound. The primary outcome was incidence of pre-eclampsia or infant birth weight ≤ 5th percentile.

Pre-eclampsia or low birth weight occurred in 88 women in the low-dose aspirin group, giving an incidence rate of 16%. Seventy-nine (14.4%) placebo comparators experienced the same result. The difference in proportion of 1.6 did not correspond to a statistically significant difference, according to the multivariate analysis (odds ratio [OR]1.14, 95% confidence interval [CI], 0.82–1.58; p=0.45).

Analysis of complete cases confirmed these results, which showed that the primary outcome occurred in 14.1% and 13.3% of the low-dose aspirin and placebo groups, respectively (p=0, 68).

Secondary outcomes, including pre-eclampsia alone, severe pre-eclampsia, pre-premature pre-eclampsia, mode of delivery, preterm delivery, and perinatal death all occurred at comparable rates between groups .

“Low-dose aspirin was not associated with a lower rate than placebo of pre-eclampsia or FGR in women identified as being at high risk for pre-eclampsia on first-day uterine artery Doppler examination. quarter,” the researchers said. “We interpret our results with caution due to the lack of power related to the insufficient number of patients recruited.”

Comments are closed.